Shanghai Yizhong Pharmaceutical Co., Ltd.

SHSE:688091 Stock Report

Market Cap: CN¥8.5b

Shanghai Yizhong Pharmaceutical Future Growth

Future criteria checks 0/6

We currently don't have sufficient analyst coverage to forecast growth and revenue for Shanghai Yizhong Pharmaceutical.

Key information

n/a

Earnings growth rate

n/a

EPS growth rate

Pharmaceuticals earnings growth18.8%
Revenue growth raten/a
Future return on equityn/a
Analyst coverage

None

Last updatedn/a

Recent future growth updates

No updates

Recent updates

Subdued Growth No Barrier To Shanghai Yizhong Pharmaceutical Co., Ltd. (SHSE:688091) With Shares Advancing 27%

Nov 20
Subdued Growth No Barrier To Shanghai Yizhong Pharmaceutical Co., Ltd. (SHSE:688091) With Shares Advancing 27%

We Think You Can Look Beyond Shanghai Yizhong Pharmaceutical's (SHSE:688091) Lackluster Earnings

Nov 08
We Think You Can Look Beyond Shanghai Yizhong Pharmaceutical's (SHSE:688091) Lackluster Earnings

There's Reason For Concern Over Shanghai Yizhong Pharmaceutical Co., Ltd.'s (SHSE:688091) Massive 34% Price Jump

Oct 01
There's Reason For Concern Over Shanghai Yizhong Pharmaceutical Co., Ltd.'s (SHSE:688091) Massive 34% Price Jump

Is Shanghai Yizhong Pharmaceutical (SHSE:688091) Using Too Much Debt?

Aug 20
Is Shanghai Yizhong Pharmaceutical (SHSE:688091) Using Too Much Debt?

What Shanghai Yizhong Pharmaceutical Co., Ltd.'s (SHSE:688091) P/E Is Not Telling You

Jul 24
What Shanghai Yizhong Pharmaceutical Co., Ltd.'s (SHSE:688091) P/E Is Not Telling You

Concerns Surrounding Shanghai Yizhong Pharmaceutical's (SHSE:688091) Performance

Apr 15
Concerns Surrounding Shanghai Yizhong Pharmaceutical's (SHSE:688091) Performance

Getting In Cheap On Shanghai Yizhong Pharmaceutical Co., Ltd. (SHSE:688091) Is Unlikely

Mar 29
Getting In Cheap On Shanghai Yizhong Pharmaceutical Co., Ltd. (SHSE:688091) Is Unlikely

In this section we usually present revenue and earnings growth projections based on the consensus estimates of professional analysts to help investors understand the company’s ability to generate profit. But as Shanghai Yizhong Pharmaceutical has not provided enough past data and has no analyst forecast, its future earnings cannot be reliably calculated by extrapolating past data or using analyst predictions.

This is quite a rare situation as 97% of companies covered by SimplyWall St do have past financial data.

Earnings and Revenue Growth Forecasts

SHSE:688091 - Analysts future estimates and past financials data (CNY Millions)
DateRevenueEarningsFree Cash FlowCash from OpAvg. No. Analysts
9/30/202425166-845N/A
6/30/2024282921735N/A
3/31/20243371367486N/A
12/31/20233601627887N/A
9/30/20233491696174N/A
6/30/2023365186112137N/A
3/31/202329416793119N/A
12/31/202223614375111N/A
9/30/20221701206092N/A
6/30/20227669-614N/A
3/31/20223832-25-10N/A
12/31/20214-4-52-49N/A
9/30/2021N/A-27-50-47N/A
6/30/2021N/A-24-46-42N/A
3/31/2021N/A-22-36-31N/A
12/31/2020N/A-22-25-20N/A
12/31/2019N/A-315-71-24N/A
12/31/2018N/A-13-14-11N/A

Analyst Future Growth Forecasts

Earnings vs Savings Rate: Insufficient data to determine if 688091's forecast earnings growth is above the savings rate (2.8%).

Earnings vs Market: Insufficient data to determine if 688091's earnings are forecast to grow faster than the CN market

High Growth Earnings: Insufficient data to determine if 688091's earnings are expected to grow significantly over the next 3 years.

Revenue vs Market: Insufficient data to determine if 688091's revenue is forecast to grow faster than the CN market.

High Growth Revenue: Insufficient data to determine if 688091's revenue is forecast to grow faster than 20% per year.


Earnings per Share Growth Forecasts


Future Return on Equity

Future ROE: Insufficient data to determine if 688091's Return on Equity is forecast to be high in 3 years time


Discover growth companies